SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oncothyreon
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (2173)5/23/2013 1:35:19 AM
From: biomachine56  Read Replies (1) of 2344
 
Looks like NVP is pursuing BKM120 in mCRC and SCCHN in combo with CTX.

What's your view on the early PX-866/CTX combo data? Seems very compelling for the N number wrt to response rates in CTX naive and, more importantly, pts with prior EGFR inhibitor therapy.

BKM120 and PX-866 don't look too different as monotherapy, except that BKM120 seems to have a wider range of toxicities, especially hyperglycemia and CNS effects.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News